ECSP10010015A - Inhibidores de proteasoma - Google Patents

Inhibidores de proteasoma

Info

Publication number
ECSP10010015A
ECSP10010015A EC2010010015A ECSP10010015A ECSP10010015A EC SP10010015 A ECSP10010015 A EC SP10010015A EC 2010010015 A EC2010010015 A EC 2010010015A EC SP10010015 A ECSP10010015 A EC SP10010015A EC SP10010015 A ECSP10010015 A EC SP10010015A
Authority
EC
Ecuador
Prior art keywords
proteasome inhibitors
compositions
treatment
methods
various diseases
Prior art date
Application number
EC2010010015A
Other languages
English (en)
Inventor
Edward J Olhava
Miheala D Danca
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38691782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010015(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of ECSP10010015A publication Critical patent/ECSP10010015A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a nuevos compuestos empleados como inhibidores de proteasoma. La invención también proporciona composiciones farmacéuticas que comprenden los compuestos de la invención y métodos para usar las composiciones en el tratamiento de varias enfermedades.
EC2010010015A 2007-08-06 2010-03-04 Inhibidores de proteasoma ECSP10010015A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/017440 WO2009020448A1 (en) 2007-08-06 2007-08-06 Proteasome inhibitors

Publications (1)

Publication Number Publication Date
ECSP10010015A true ECSP10010015A (es) 2010-04-30

Family

ID=38691782

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010015A ECSP10010015A (es) 2007-08-06 2010-03-04 Inhibidores de proteasoma

Country Status (32)

Country Link
EP (3) EP2178888B1 (es)
JP (1) JP5261488B2 (es)
KR (6) KR20140042933A (es)
CN (1) CN101772507B (es)
AU (1) AU2007357338B2 (es)
BR (1) BRPI0721905B8 (es)
CA (1) CA2695082C (es)
CY (2) CY1113386T1 (es)
DK (1) DK2178888T3 (es)
EA (1) EA028622B1 (es)
EC (1) ECSP10010015A (es)
ES (1) ES2390606T3 (es)
FR (1) FR17C1011I2 (es)
GE (1) GEP20125599B (es)
HR (1) HRP20120745T1 (es)
HU (1) HUS1700018I1 (es)
IL (4) IL203641A (es)
LT (1) LTC2178888I2 (es)
LU (1) LUC00013I2 (es)
MY (1) MY161991A (es)
NL (1) NL300871I2 (es)
NZ (1) NZ582693A (es)
PH (1) PH12014500053A1 (es)
PL (1) PL2178888T3 (es)
PT (1) PT2178888E (es)
RS (1) RS52435B (es)
SG (1) SG10201508712QA (es)
SI (1) SI2178888T1 (es)
TN (1) TN2010000060A1 (es)
UA (1) UA97536C2 (es)
WO (1) WO2009020448A1 (es)
ZA (1) ZA201000348B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576206B2 (en) † 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
EP2623113B1 (en) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Compound for enzyme inhibition
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
CA2701778C (en) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
SI2318419T2 (sl) 2008-06-17 2025-10-30 Takeda Pharmaceutical Company Limited Spojine boronat estra in njihovi farmacevtski sestavki
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
NZ600786A (en) 2009-12-22 2013-12-20 Cephalon Inc Proteasome inhibitors and processes for their preparation, purification and use
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
AU2011235227B2 (en) 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
WO2012177835A1 (en) * 2011-06-22 2012-12-27 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
EP4706663A3 (en) * 2011-08-30 2026-05-20 Trustees Of Tufts College FAP-ACTIVATED PROTEASOME INHIBITORS USED TO TREAT SOLID TUMORS
SG10201605152SA (en) * 2011-12-22 2016-08-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
WO2013112598A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Method of treatment of nasopharyngeal caner
WO2013112601A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
CN109180780B (zh) * 2012-07-26 2022-03-18 圣特莱国际公司 多肽环氧酮化合物
JP2013006855A (ja) * 2012-09-03 2013-01-10 Millennium Pharmaceuticals Inc プロテアソーム阻害剤
MX2015006715A (es) * 2012-12-03 2015-08-14 Hoffmann La Roche Compuestos de acido triazolboronico sustituido.
US20160250238A1 (en) 2013-10-03 2016-09-01 Millennium Pharmaceuticals, Inc. Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis
UA121389C2 (uk) 2014-05-20 2020-05-25 Мілленніум Фармасьютікалз, Інк. Борвмісні інгібітори протеасом для застосування після первинної протиракової терапії
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
MA41555A (fr) * 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
WO2016205790A2 (en) 2015-06-19 2016-12-22 Hanlin Scientific, Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
CN106608883A (zh) * 2015-10-21 2017-05-03 北京大学 蛋白酶体抑制剂mln9708的合成方法
CN107400142B (zh) * 2016-05-19 2019-11-19 成都奥璟生物科技有限公司 一种硼酸和硼酸酯类化合物及其应用
CN106008572B (zh) * 2016-05-23 2018-08-17 成都千禧莱医药科技有限公司 一类二肽硼酸化合物及制备方法和用途
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
JP7179721B2 (ja) 2016-06-21 2022-11-29 オリオン・オフサルモロジー・エルエルシー 複素環式プロリンアミド誘導体
JP6802899B2 (ja) * 2016-07-25 2020-12-23 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． 置換ボロン酸化合物、該化合物を含む医薬組成物およびその使用
CN108440583B (zh) * 2017-01-23 2020-12-04 成都奥璟生物科技有限公司 一种新的硼酸衍生物及其药物组合物
WO2018160717A1 (en) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
CN108794516A (zh) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 硼酸和硼酸酯类化合物及其制备方法和用途
CN109305980B (zh) * 2017-07-28 2022-10-11 成都奥璟生物科技有限公司 一种硼酸酯化合物、其合成方法及其用途
ES2901022T3 (es) 2017-08-25 2022-03-21 Synthon Bv Procedimiento para la preparación de ixazomib y sus intermedios
JP2018024694A (ja) * 2017-10-03 2018-02-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
CN115403603A (zh) * 2018-09-14 2022-11-29 成都奥璟生物科技有限公司 一种硼酸酯类药物及其用途
CN110357787A (zh) * 2019-08-02 2019-10-22 苏州艾和医药科技有限公司 依沙佐米合成工艺研究
US12589103B2 (en) 2019-10-07 2026-03-31 Cornell University Antimicrobial and antiviral effects of C2-C7 alkyl boronic acids
CN110950897B (zh) * 2019-12-12 2021-05-28 山东大学 一种组蛋白去乙酰化酶、蛋白酶体双靶点抑制剂及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2435146C (en) 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
EP1399468B1 (en) 2001-05-30 2006-02-15 Novartis AG 2-((n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl)-amino)-alkylboronic acid derivatives
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
TWI345465B (en) * 2003-08-14 2011-07-21 Cephalon Inc Proteasome inhibitors and methods of using the same
ES2899606T3 (es) 2004-03-30 2022-03-14 Millennium Pharm Inc Síntesis de compuestos de ésteres y ácidos borónicos
WO2006008660A2 (en) 2004-07-20 2006-01-26 Affinium Pharmaceuticals, Inc. Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk)
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
GB0513349D0 (en) 2005-06-29 2005-08-03 Torres Manel Non-woven fabric
CN101247799B (zh) 2005-07-05 2013-03-27 塔夫茨大学信托人 成纤维细胞活化蛋白α的抑制剂

Also Published As

Publication number Publication date
LTC2178888I2 (lt) 2018-03-12
AU2007357338B2 (en) 2014-03-20
HK1143595A1 (en) 2011-01-07
LUC00013I1 (es) 2017-04-06
CY2017016I1 (el) 2017-07-12
EP2178888A1 (en) 2010-04-28
CN101772507A (zh) 2010-07-07
IL242292A (en) 2017-12-31
EA028622B1 (ru) 2017-12-29
SG10201508712QA (en) 2015-11-27
ES2390606T3 (es) 2012-11-14
EA201070247A1 (ru) 2010-06-30
KR20160040735A (ko) 2016-04-14
PH12014500053B1 (en) 2015-03-30
CN101772507B (zh) 2012-12-12
ZA201000348B (en) 2011-03-30
EP2178888B1 (en) 2012-07-04
RS52435B (sr) 2013-02-28
KR101831674B1 (ko) 2018-02-23
JP5261488B2 (ja) 2013-08-14
IL242290A (en) 2017-12-31
EP2527347A1 (en) 2012-11-28
IL242290A0 (en) 2015-11-30
SI2178888T1 (sl) 2012-11-30
IL242292A0 (en) 2015-11-30
IL242291A0 (en) 2015-11-30
AU2007357338A1 (en) 2009-02-12
DK2178888T3 (da) 2012-10-01
CY1113386T1 (el) 2016-06-22
NL300871I2 (nl) 2017-12-07
NZ582693A (en) 2012-01-12
KR20140042932A (ko) 2014-04-07
IL203641A (en) 2015-11-30
KR20150010802A (ko) 2015-01-28
CY2017016I2 (el) 2017-07-12
MY161991A (en) 2017-05-31
BRPI0721905B1 (pt) 2020-11-17
HUS1700018I1 (hu) 2017-05-29
JP2010535759A (ja) 2010-11-25
GEP20125599B (en) 2012-08-10
EP3210987A1 (en) 2017-08-30
PH12014500053A1 (en) 2015-03-30
FR17C1011I1 (es) 2017-05-26
PL2178888T3 (pl) 2012-11-30
BRPI0721905A2 (pt) 2014-02-25
KR20170004031A (ko) 2017-01-10
KR20140042933A (ko) 2014-04-07
UA97536C2 (xx) 2012-02-27
BRPI0721905B8 (pt) 2021-05-25
WO2009020448A1 (en) 2009-02-12
HRP20120745T1 (hr) 2012-10-31
IL242291A (en) 2017-12-31
FR17C1011I2 (fr) 2018-04-27
LUC00013I2 (es) 2017-06-19
KR20100059811A (ko) 2010-06-04
TN2010000060A1 (en) 2011-09-26
KR101474831B1 (ko) 2014-12-19
CA2695082A1 (en) 2009-02-12
LTPA2017010I1 (lt) 2017-05-10
CA2695082C (en) 2015-07-28
PT2178888E (pt) 2012-10-04

Similar Documents

Publication Publication Date Title
CR20160015A (es) Compuestos de éster boronato y composiciones farmacéuticas de los mismos
CO6630162A2 (es) Derivados del ácido 1-amino -2-ciclopropiletilboronico
CR20160475A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
CR20150610A (es) Compuestos de pirimidino sustituido y derivados para combatir plagas de animales
AR075442A1 (es) Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
SV2011003855A (es) Heteroarilos sustituidos
DOP2010000118A (es) Compuestos de tienopirimidina y pirazolopirimidina como inhibidores de mtor cinasa y p13 cinasa
GT200500237A (es) Derivados de pirimidina
ECSP088884A (es) Compuestos heterociclicos fusionados y su uso como moduladores de mglur5
MX338535B (es) Inhibidores de ibat para el tratamiento de enfermeades hepaticas.
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
ECSP11011082A (es) Compuestos, composición farmaceutica y métodos para utilizarse en el tratamiento de desórdenes metabólicos
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
CR20140553A (es) Compuestos de fenoxietil piperidina
CO6630193A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa seleccionada
UY31000A1 (es) Oxoisoxazoles como inhibidores de lipasas y fosfolipasas
UY31427A1 (es) Derivados 1,2,4-triazol amino como moduladores de mglur5
NI201200103A (es) NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75
DOP2010000027A (es) Inhibidores de proteasoma
CR11242A (es) Inhibidores de proteasoma
UY32569A (es) Derivados punteados con sulfuro como moduladores de mglur5 733
UY31289A1 (es) Nuevos derivados de la quinoliniloxipiperidina y pirrolidina, su preparacion, composiciones farmaceuticas que los contiene y sus usos en el tratamieno de enfermedades